Clinical trials: Giant Cells Arteritis
Giant Cell Arteritis (GCA)
Kinetics of C-Reactive Protein in Giant Cell Arteritis Following Glucocorticoid Initiation: A Pilot Study (GIDEON)
We propose to analyze the kinetics of the main marker of inflammation in GCA in order to understand its links with initial clinical manifestations and the possible appearance of complications and/or relapses.
- Trial name
- GIDEON (NCT07720804)
- Testing
- Blood tests to measure CRP
- Volunteers
- 40 people
- Sponsor
- University Hospital, Limoges
Giant Cell Arteritis
TARGET GCAT Registry
A longitudinal post-marketing surveillance registry nested within the UK GCA Consortium that assesses the effectiveness and safety of tocilizumab in controlling refractory or relapsing forms of GCA in patients who require…
- Trial name
- NCT04049071
- Where
- 34 sites in United Kingdom
- Volunteers
- 80 people
- Sponsor
- University of Leeds
Giant Cell Arteritis
Impact of the Spatial Resolution of Several Contrast-enhanced 3D T1-WI Sequences When Diagnosing Giant Cell Arteritis (GCA)
Giant cell arteritis (GCA) (or Horton's disease) is a segmental and focal inflammatory arteritis affecting large and medium-sized arteries.
- Trial name
- SPARTA (NCT05854927)
- Testing
- 3D T1 MRI sequences injected with fat saturation and black blood
- Where
- France
- Volunteers
- 133 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Giant Cell Arteritis (GCA), Doppler Ultrasound
Halo Sign Vanishing Time After Steroids Outbreak in GCA Patients
Giant cell arteritis (GCA) is a rare disease characterized by vasculitis of the large arterial trunks targeting the thoracic aorta and its dividing branches, affecting adults over the age of 50.
- Trial name
- Halo-A (NCT07060274)
- Testing
- Doppler Ultrasound
- Where
- 6 sites in France
- Volunteers
- 64 people
- Sponsor
- Centre Hospitalier le Mans
Giant Cell Arteritis
Evaluation of PET/CT of Cephalic Arteries for the Diagnosis of Giant Cell Arteritis
Giant cell arteritis (GCA) is the most common vasculitis in adults. The diagnosis of GCA is evoked by the association of clinical signs and biological anomalies (inflammatory syndrome) in patients over 50 years of age.
- Trial name
- Cervico-TEP et (NCT05246540)
- Testing
- Data collection
- Where
- France
- Volunteers
- 70 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Takayasu's Arteritis, Giant Cell Arteritis
Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis
Background: Vasculitis is a group of diseases that inflame and damage blood vessels and tissue. It can cause many medical problems. Few tests can diagnose the disease, and none can reliably predict a relapse.
- Conditions
- Takayasu's Arteritis, Giant Cell Arteritis, Polyarteritis Nodosa, Relapsing Polychondritis
- Trial name
- NCT02257866
- Where
- United States
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Giant Cell Arteritis
Association of Ultrasonographic Temporal Artery Lesions and Relapse in Patients With Giant Cell Arteritis
Ultrasound evaluation of the temporal and axillary arteries is currently well recognized in the field of giant cell arteritis (GCA), a disease primarily affecting medium- and large-caliber vessels.
- Trial name
- ALERT (NCT06894602)
- Where
- 2 sites in France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Brest
Giant Cell Arteritis (GCA)
Bosentan in the Treatment of Giant Cell Arteritis
The purpose of this study is to determine whether a treatment with 3 months of bosentan associated to standard therapy might be superior to glucocorticoids alone in term of failure free survival at 12 months
- Trial name
- BOSICART (NCT06957002)
- Testing
- Bosentan, Glucocorticoids
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Giant Cell Arteritis
A Study to Evaluate Guselkumab for the Treatment of Participants With New-onset or Relapsing Giant Cell Arteritis
The primary purpose of this study is to evaluate the efficacy of guselkumab compared to placebo, in combination with a 26-week glucocorticoid (GC) taper regimen, in adult participants with new-onset or relapsing giant cell…
- Trial name
- THEIA (NCT04633447)
- Testing
- Guselkumab
- Where
- 30 sites in United States, Belgium and 7 more
- Volunteers
- 53 people
- Sponsor
- Janssen Research & Development, LLC
Giant Cell Arteritis
Hydroxychloroquine in Giant Cell Arteritis
Cortico-dependence is frequent in giant cell arteritis patients, and no drugs has proved its ability to prevent corticodependence.
- Trial name
- NCT00430807
- Where
- 23 sites in France
- Volunteers
- 75 people
- Sponsor
- University Hospital, Toulouse
Behcet's Disease, Churg-Strauss Syndrome
VCRC Patient Contact Registry Patient-Reported Data Validation Study
The purpose of this study is to provide validation of patient-reported data in the VCRC Patient Contact Registry by comparing patient-reported data with data provided by the physician who is the primary provider caring for the…
- Conditions
- Behcet's Disease, Churg-Strauss Syndrome, Giant Cell Arteritis, Wegener Granulomatosis
- Trial name
- NCT02190942
- Where
- United States
- Volunteers
- 198 people
- Sponsor
- University of South Florida
Behcet's Disease, Churg-Strauss Syndrome
Educational Needs of Patients With Systemic Vasculitis
A cross-sectional study design and online questionnaire was used to assess the informational needs of patients with several different types of systemic vasculitis.
- Conditions
- Behcet's Disease, Churg-Strauss Syndrome, Vasculitis, Central Nervous System, Giant Cell Arteritis
- Trial name
- NCT02190929
- Where
- United States
- Volunteers
- 386 people
- Sponsor
- University of South Florida
Adrenal Insufficiency, Polymyalgia Rheumatica (PMR)
Hydrocortisone and Placebo in Patients With Symptoms of Adrenal Insufficiency After Cessation of Glucocorticoid Treatment
Cortisol, a glucocorticoid (GC) hormone secreted from the adrenal glands, is essential for survival. Cortisol also possesses anti-inflammatory actions and GC formulations (prednisolone) are used to treat many inflammatory…
- Conditions
- Adrenal Insufficiency, Polymyalgia Rheumatica (PMR), Giant Cell Arteritis (GCA)
- Trial name
- REPLACE (NCT05193396)
- Testing
- Hydrocortisone
- Where
- 3 sites in Denmark
- Volunteers
- 100 people
- Sponsor
- Marianne Andersen
Rheumatoid Arthritis, Polymyalgia Rheumatica
Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol.
The purpose of this study is to determine wich treatment is the most effective in prevention of glucocorticoid-induced osteoporosis in patients with rheumatic diseases.
- Conditions
- Rheumatoid Arthritis, Polymyalgia Rheumatica, Giant Cell Arteritis, Polymyositis
- Trial name
- NCT00138983
- Testing
- Alendronate versus alfacalcidol (1-alpha OH vitamin D)
- Where
- Netherlands
- Volunteers
- 200 people
- Sponsor
- UMC Utrecht
Giant Cell Arteritis, Optic Ischaemic Neuropathy
Efficacy of Tocilizumab for the Treatment of Acute AION Related to GCA
AION is the main cause of blindness in patients with GCA. High dose steroid is the reference treatment of this condition, but medical unmet need remains.
- Trial name
- TOCIAION (NCT04239196)
- Testing
- tocilizumab and IV steroids combination, IV steroids combination alone
- Where
- 10 sites in France
- Volunteers
- 58 people
- Sponsor
- Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
GCA, TOCILIZUMAB
Ultra-short Glucocorticosteroids and Tocilizumab Therapy in GCA Patients
The objective of our study is to evaluate the functional and morphological imaging variations at 24 and 52 weeks compared to baseline during TCZ-treatment and 6 months after the suspension of TCZ.
- Conditions
- GCA, TOCILIZUMAB, Glucocorticoids, PET
- Trial name
- TOPAZIO (NCT05394909)
- Testing
- Tocilizumab 162Mg/0.9Ml Autoinjector
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Azienda USL Reggio Emilia - IRCCS
Giant Cell Arteritis, Polymyalgia Rheumatic (PMR)
Giant Cell Arteritis - Ways to Precision Medicine
Long-term follow-up of aortal adverse events, as well as glucocortioid-associated adverse events in patients with polymyalgia rheumatica (PMR) and giant cell arteritis (GCA).
- Trial name
- NCT07084480
- Where
- Germany
- Volunteers
- 400 people
- Sponsor
- Wuerzburg University Hospital
Giant Cell Arteritis, Takayasu Arteritis
PET Imaging of Giant Cell and Takayasu Arteritis
While 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging is often included in the diagnostic work-up of patients with large-vessel vasculitis (LVV), 18F-FDG lacks specificity for inflammatory cells and has…
- Trial name
- PITA (NCT04071691)
- Testing
- PET-MRI
- Where
- 2 sites in United Kingdom
- Volunteers
- 27 people
- Sponsor
- University of Cambridge
Rheumatoid Arthritis, Ankylosing Spondylitis
PatientSpot Formerly Known as ArthritisPower
Patient Power is a patient research network and database (registry) to collect prospective information about demographics, self-reported diagnoses and medications, and willingness to participate in research from participants with…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout
- Trial name
- NCT03840928
- Where
- United States
- Volunteers
- 40,000 people, healthy volunteers welcome
- Sponsor
- Global Healthy Living Foundation
Giant Cell Arteritis, Neurovascular Disorder
Efficacy of Tocilizumab in Association to Steroids in Giant Cell Arteritis With Cerebro-vascular Involvement
A French multicenter randomised and placebo-controlled study recruiting patients who present neurovascular involvement related to GCA (> 60 years) with symptomatic (stroke) or asymptomatic forms.
- Trial name
- TOGIAC (NCT04888221)
- Testing
- Tocilizumab
- Where
- France
- Volunteers
- 66 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris